Category: Press Releases

QUEBEC CITY, Dec. 07, 2022 (GLOBE NEWSWIRE) — LeddarTech^®, a global leader in providing the most flexible, robust and accurate ADAS and AD software technology, is pleased to announce the launch of the LeddarVision Front-View-E (LVF-E) and LeddarVision Front-View-H (LVF-H), two distinct comprehensive low-level fusion and perception software stacks that optimally combine sensor modalities for Level 2/2+ ADAS applications achieving a 5* NCAP 2025/GSR 2022 rating.

LeddarTech addresses the challenges Tier 1-2 suppliers and OEMs struggle with when developing Level 2/2+ ADAS applications, such as solving safety issues and finding scalable fusion and perception software that offers high performance at a low cost. The LeddarVision Front-View (LVF) family of automotive software products, developed by LeddarTech, addresses these challenges.

LVF-E (LeddarVision Front-Entry): Created for customers seeking to develop entry-level ADAS safety and highway assistance L2/L2+ applications, LVF-E is a comprehensive front-view fusion and perception stack for entry-level ADAS L2/L2+ highway assist and 5-star NCAP 2025/GSR 2022. LeddarTech’s low-level fusion (LLF) technology pushes the performance envelope, doubling the effective range of the sensors and enabling for the first time a solution with only a single 1.2-megapixel 120-degree front camera and two short-range front corner radars in a 1V2R configuration. Low-cost sensing, together with efficient implementation on the TDA4L platform, achieves the lowest system cost for L2/L2+ entry-level ADAS. B-sample is planned for Q2 2023, targeting vehicle SOP in 2025/6.

LVF-H (LeddarVision Front-High): The premium companion fusion and perception stack in the front-view product family. With sensor configuration extended to 1V5R based on a single 3-megapixel 120-degree camera, single front medium-range radar and four short-range corner radars, the stack extends the perception support to highway assist applications, including 160 km/h adaptive cruise control, 200-meter range and semi-automated lane change. It also enhances the NCAP 2025 support for overtaking/ reverse/dooring scenarios. Furthermore, with efficient implementation on the TDA4L platform and a single Hailo-8 deep-learning accelerator, low-cost sensing achieves economic front-view L2/L2+ premium ADAS. B-sample is planned for Q3 2023, targeting vehicle SOP in 2026.

The LeddarVision Front-View (LVF) family of products is designed to meet the needs of their customers:

High-Performance and Cost-Effective

• LeddarVision’s low-level fusion (LLF) technology pushes the performance envelope, doubling the effective range of the sensors.
• The products’ lowest-cost sensing feature and efficient implementation on the TDA4L platform achieve the lowest system costs.
• Superior accuracy in object separation and longitudinal position measurement on highways enable higher-performing adaptive cruise control implementation.

Safety

• LVF products address 5* NCAP 2025/GSR 2022 safety applications.
• Include a built-in redundancy feature to accommodate sensor failures, degradations and conflicts.
• Provide an increased safety feature due to superior accuracy in object separation and longitudinal position measurement.

Flexible and Scalable

• A comprehensive front-view fusion and perception stack that supports entry-level to premium ADAS highway assist Level 2/2+ applications.

Interested customers can contact LeddarTech for “A” samples of the LVF-E and LVF-H products.

“I am excited to announce our newest sensor fusion and perception products to support entry-level to premium ADAS highway assist Level 2/2+ applications,” stated Mr. Charles Boulanger, CEO of LeddarTech. “The market’s need for a high-performance sensor fusion and perception product while also being cost-effective, flexible and scalable and has never been greater, and our LVF family of products addresses that need,” Mr. Boulanger continued. “Our mission at LeddarTech is to improve safety and the quality of life by enabling ADAS and AD applications, and this is accomplished with the release of these two products that achieve 5* NCAP 2025/GSR 2022 ratings.” Mr. Boulanger concluded: “I look forward to announcing additional products in 2023 that will continue to meet the needs of the industry and improve the quality of people’s lives.”

LeddarTech’s LeddarVision LVF-E and LVF-H software products will be highlighted at CES 2023, January 5-8 in Las Vegas, within LeddarTech’s booth # 5475, LVCC West Hall.

About LeddarTech

LeddarTech, a global software company founded in 2007, develops and provides comprehensive perception solutions that enable the deployment of ADAS and autonomous driving applications. LeddarTech’s automotive-grade software applies AI and computer vision algorithms to generate highly accurate 3D models of the environment, allowing for better decision making and safer navigation. This high-performance, scalable, cost-effective technology is leveraged by OEMs and Tier 1-2 suppliers for the efficient implementation of automotive and off-road vehicle solutions.

LeddarTech is responsible for several remote-sensing innovations, with over 140 patents granted or applied for that enhance ADAS and AD capabilities. Reliable perception is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to become the most widely adopted sensor fusion and perception software solution.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Investor relations contact and website: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

GlobeNewswire Distribution ID 8708692

Leading the carbon fiber industry on a global scale

St. Louis, Missouri, USA, Dec. 06, 2022 (GLOBE NEWSWIRE) — Zoltek Corporation, the largest global manufacturer of industrial grade carbon fiber, has recently celebrated the 80^th birthday of its founder, Zsolt Rumy.

Born in December 1942 in Budapest, Hungary, Mr. Rumy was a carbon fiber industry pioneer that ultimately changed the carbon fiber world.  He created the first industrial-grade carbon fiber made to compete against other common building materials, and created Zoltek Corporation to drive the commercialization of carbon fibers.

Mr. Rumy fled Soviet communism after the Hungarian Revolution in 1956, and arrived in the US as a 14-year old war refugee through the International Red Cross and Catholic Charities.   He later graduated with a chemical engineering degree from the University of Minnesota, accepted a position with Monsanto Company and moved to St. Louis, Missouri in 1966. After several years of corporate sales and engineering jobs in the chemicals industry, he started his own distribution business in 1975.   After years of selling carbon and graphite products, he plunged into carbon fiber manufacturing in 1988 with the acquisition of Stackpole Fibers in Lowell, Massachusetts.

His vision of a low-cost carbon fiber began on a pilot line in St. Louis, MO, and later became realized after acquiring an acrylic fiber factory, Magyar Viscosa, back in his native Hungary.  He led a team of engineers that were able to convert this acrylic fiber factory to the world’s first low-cost carbon fiber factory.  Zoltek repeated this feat by acquiring a second acrylic fiber factory in Mexico, and the rest is history.

In 2014, Zoltek was acquired by Toray Industries of Japan, who at the time was the world’s largest aerospace carbon fiber producer.  With the support of the Toray Group, Zoltek has now grown to the largest carbon fiber manufacturer in the world, with more than 30,000 MT of annual capacity.

“Zsolt is a true pioneer who lived the American dream.  He built a company and changed the carbon fiber industry forever.  We are all honored to be part of his journey and grateful for his leadership and friendship”, EVP of Sales & Marketing Dave Purcell. “Now it’s our job to carry his vision forward and bring our low-cost carbon fiber to new applications around the world,” he added.

“The Will To Do, The Soul Dare” is an autobiography that details Zsolt’s extraordinary life experiences and his visionary spirit and courage that revolutionized the carbon fiber industry.  Zsolt’s book is available in major book stores and Amazon.  You may also request a free copy of Zsolt’s book (while supplies last) by sending your request to jschmidt@twinspringsinv.com.

Zsolt Rumy and Dave Purcell are current board members of Zoltek Corporation.

About Zoltek: Zoltek Corporation is the most trusted manufacturer of cost-efficient and customer-centric industrial grade carbon fiber used for automotive parts, wind turbine blades, thermoplastic compounding, marine infrastructure, and many more. In 2014, Zoltek joined the Toray Group (Japan) which has advanced the company’s technology and strengthened the technical and financial resources and positioned the company for further growth as the most reliable global leader of carbon fiber.

For more information, you may visit www.zoltek.com or follow us on any of our social media channels including www.linkedin.com/company/zoltek/ and https://www.facebook.com/ZoltekCorp. For more information about Toray Group, you may visit www.toray.com 

Attachment

• Zsolt Rumy

Jen Olson

GlobeNewswire Distribution ID 8709508

Graid Technology & Liqid partner to deliver best-in-class NVMe data protection and performance

SANTA CLARA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — Graid Technology, the multi-award-winning data protection provider and developer of the only RAID card to deliver the full performance capability of NVMe SSDs, and Liqid, a leading provider of composable disaggregated infrastructure (CDI) and NVMe storage solutions, today announced a cooperative agreement to partner in customer engagements. The relationship will be focused on providing data protection along with elimination of I/O bottlenecks for customers deploying Liqid’s Honey Badger NVMe flash devices and CDI solutions.

The solution allows the bank to deliver faster credit decisions and automate workflows, enhancing business agility and productivity.

SYDNEY, Dec. 06, 2022 (GLOBE NEWSWIRE) — Nucleus Software transforms Bank of Sydney towards digital customer experience with FinnOne neo solution. Bank of Sydney is an organization committed to providing genuine value for its people, customers, communities, and partners. To deliver responsible and sustainable growth, the bank has a clear strategy that’s supported by technological transformation. Core strategic initiatives which focus on driving efficiency and effectiveness, with an emphasis on automation, building workflows and digitizing processes across the business have significantly enhanced the banking experience for both the Bank’s customers and employees.

Through the digital lending platform FinnOne neo from Nucleus Software, Bank of Sydney will be able to provide an improved customer experience with a faster approval process and communications. By employing the platform’s real-time dashboard for tracking and reporting, the bank aims to enhance both the internal and external transparency, and accountability of its processes.

CEO of the Bank of Sydney, Mr. Miltos Michaelas, was delighted by the progress and said, “By adopting a plug & play platform like that of FinnOne neo from Nucleus Software, Bank of Sydney is enabled to deliver faster and more efficient services in a seamless manner. There is a growing need for integration with various sources of data for swift and precise application on-boarding and decision-making in the Financial Services Industry. FinnOne neo provides the capability to integrate with third-party systems to collect, combine, and use data for all of Bank of Sydney’s lending requirements.”

Mr. Parag Bhise, CEO of Nucleus Software, was also pleased to state that “Our lending platform is highly configurable, thus removing the need to create a new expensive and complex system from scratch. We expect that the deployment of our FinnOne neo platform will further empower Bank of Sydney to improve banking experiences for their customers”.

With successful and smooth go-live of the new platform, many Bank of Sydney applications are now processed through FinnOne neo. The adoption of the platform establishes a strong foundation for further integration and growth for the Bank.

About Bank of Sydney: For more information, please visit: www.banksyd.com.au

About Nucleus Software:

Nucleus Software Exports Ltd. is a publicly traded (BSE: 531209, NSE: NUCLEUS), software product company that provides lending, transaction banking products to global financial leaders.

Nucleus Software powers the operations of 200+ Financial Institutions across 50+ countries, supporting retail and corporate lending, cash management, mobile and internet banking. Its products facilitate 26+ million transactions/day, managing over US $ 200 billion of loans and enabling 300,000+ daily users.

Nucleus Software’s flagship products, built on the latest technology:

• FinnOne neo: Next-generation digital lending solution, built on an advanced technology platform.
• FinnAxia: An integrated global transaction banking solution used by banks worldwide.
• PaySe: World’s first online & offline digital payment solution created to democratize money.

For more information, please visit: http://www.nucleussoftware.com

Contact Information:
Deepika Gulabani
marcom@nucleussoftware.com
+91-9289708877

This content was issued through the press release distribution service at Newswire.com.

GlobeNewswire Distribution ID 8709321

Magic Johnson and Judge Louis Freeh spoke at Acronis Summit 2022

Magic Johnson and Judge Louis Freeh spoke at Acronis Summit 2022

At this year’s #CyberFit Summit, Acronis rolled out the red carpet for insightful speakers and announced two new products along with the promotion of the company’s new chief sales officer.

BURLINGTON, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) — Coming out of #CyberFit Summit 2022, Acronis, the global leader in Cyber Protection, is poised for exciting developments in cybersecurity in the new year. In front of more than 1,000 attendees, 50 journalists and 100 speakers, Acronis unveiled the upcoming releases of Acronis Advanced Automation and Acronis Advanced Security + EDR, and introduced the newest member of the c-suite, Chief Sales Officer Katya Ivanova.

Through superstar keynotes, expert panels, and hands-on workshops, MSPs and IT professionals were left with deeper insights into the threat landscape, new business-building tips and a path to accelerate growth while securing customer loyalty.

Acronis CEO Patrick Pulvermueller kicked off the three-day event in Miami Beach with his keynote. He opened with staggering statistics illustrating the enormity of data today. There are currently 10 million physical servers on Earth, and data creation has increased 90-fold just since 2010. To protect this sheer enormity of data, consolidation and simplification are the future. Pulvermueller tied in the tagline of #CyberFit Summit – cyber protect the future – and emphasized Acronis’ unwavering focus on partner success, innovation and simplification.

“The continuous rise of cyber protection the defining moment of our industry,” said Patrick Pulvermueller, CEO at Acronis. “During our #CyberFit Summit, we were thrilled to share our vision for Acronis and how cyber protection will evolve in the year ahead. At Acronis, we’re continuing to set our partners and customers up for success.”

In multiple sessions at the Acronis #CyberFit Summit in Miami, cybersecurity analysts and experts provided an inside look at how cyberattacks attacks work, how MSPs are impacted and how Acronis Cyber Protection Solutions prevent them. Other notable keynotes from the event included former FBI Director, Judge Louis Freeh talking about his experience with the mafia and ransomware; basketball legend and serial entrepreneur, Earvin “Magic” Johnson, giving an inspirational speech on how he has parlayed the skills and tenacity acquired on the court into a winning formula for his successful business ventures; Acronis founder and Chief Research Officer Serg Bell’s discussion about expanding the future of MSPs; and the #CyberWomen keynote, where several influential women speculated on the bright future for women in the cyber field.

#CyberFit Summit sponsors Silvereye Technologies and Galactic Advisors were thrilled to be part of the event. “A decade ago, excellent cybersecurity and data protection was a luxury. Now that ransom payments are skyrocketing, companies are suffering huge hits, not only financially but also to their reputation. Cybersecurity is now a necessity,” said Jennifer Pierce at Galactic Advisors. “Events like #CyberFit Summit are an excellent opportunity to share knowledge and position our partners to make a significant positive impact in their communities around the world.”

Cameron May, Chief Strategist of Silvereye Technologies, added, “The Acronis Platform is a cornerstone for cybersecurity. The Acronis Summit combines a wide range of technologies, industry leaders and strategists together for what Silvereye views as the most important event of the year.”

MSPs, CISOs, CIOs and architects left #CyberFit Summit laden with bursting camera reels (more than 8,000 photos were taken over the three days), with great new ideas and with excitement for the Acronis developments to come in early 2023. Perhaps, attendees also returned home with a need to rest their feet: the average conference attendee walked 25,000 each day. Now, that’s #CyberFit.

To learn more about the Acronis #CyberFit Summit and register for next year’s event taking place October 16 – 18, 2023 in Miami Beach, Florida, visit: https://promo.acronis.com/summit-2023-pre-register.html.

About Acronis
Acronis unifies data protection and cybersecurity to deliver integrated, automated cyber protection that solves the safety, accessibility, privacy, authenticity, and security (SAPAS) challenges of the modern digital world. With flexible deployment models that fit the demands of service providers and IT professionals, Acronis provides superior cyber protection for data, applications, and systems with innovative next-generation antivirus, backup, disaster recovery, and endpoint protection management solutions powered by AI. With advanced anti-malware powered by cutting-edge machine intelligence and blockchain based data authentication technologies, Acronis protects any environment – from cloud to hybrid to on premises – at a low and predictable cost.

Founded in Singapore in 2003 and incorporated in Switzerland in 2008, Acronis now has more than 2,200 employees in 40 locations in 19 countries. Acronis Cyber Protect solution is available in 26 languages in over 150 countries and is used by over 20,000 service providers to protect over 750,000 businesses.

Press contacts:

Karl Bateson

Global Director PR & Communications
Karl.Bateson@acronis.com

A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3407d1d8-e41f-431b-8735-ea28f963effe

GlobeNewswire Distribution ID 8708767

• Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer’s disease (AD) patients
• TB006 also demonstrated improvements in PET and MR imaging, consistent with dissolution of toxic amyloid plaque shown in preclinical studies
• Ongoing open-label extension study with more than 100 participants is generating long-term safety and efficacy data

FOSTER CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — TrueBinding Inc. a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases and other serious diseases, highlighted the unique method of action (MOA) of TB006, an investigational monoclonal antibody against Galectin-3 (Gal-3) for the treatment of mild to severe AD, at the recent 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.

Aβ, p-Tau and other pathogenic factors are not considered toxic when they exist as monomers; however, when they are aggregated and become oligomers, they become very toxic, which leads to neuronal death and neuroinflammation. Gal-3 has been shown to play a detrimental role in AD pathology by promoting the aggregation of Aβ, p-Tau, Apo-E4 and other pathogenic factors. In preclinical studies, TB006, a humanized monoclonal antibody, was shown to block Gal-3 and dissolve the toxic aggregates, which reversed disease progress in animal models of AD.

“Our monoclonal antibody, TB006, targets Gal-3, which acts as a glue and has a role in the formation of toxic protein oligomers that compromise normal neuronal function in the brain and leads to disease progression,” said Dongxu Sun, Ph.D., chief executive officer of TrueBinding. “Unlike other antibodies in development that target the components of the aggregates, TB006 is unique in that it targets what may be the key nucleating factor for the aggregates to inhibit its activity. We are encouraged by the early clinical data and look forward to advancing our understanding of TB006 and its potential to improve cognition and functioning with an ambitious goal of potentially reversing the course of AD.”

Dr. Sun continued, “Our Phase 1b/2 proof-of-concept trial demonstrated the potential of TB006 to improve cognition and function in patients with Alzheimer’s disease with a short one-month weekly treatment regimen. Improvements in patient cognition and function were seen as early as 15 days after the first treatment, and continued through day 36, only diminishing once we stopped treatment with TB006. Notably, this efficacy was observed across the patient population, whose disease severity ranged from mild to severe. Beyond the quantitative clinical measures we track, we’ve also received an overwhelming number of touching personal stories from participating physicians and caregivers about the dramatic improvement in symptoms of trial participants and the hope they have for a safe and effective treatment for this debilitating disease.”

“There is an immense need for disease modifying treatments that can help the more than 6.5 million patients diagnosed with Alzheimer’s disease in the U.S,” said Malisa Agard, MD, principal investigator, Conquest Research. “Unfortunately, our existing treatment options are quite limited, so I was excited to review the data from the TB006 trial. Despite it being early-stage data, it gives me a great deal of hope in the potential of TB006 to help the millions of patients who are suffering now and, additionally, the millions more who are likely to develop this disease in the future.”

Data from the Phase 1b/2 trial presented at CTAD and more information on the promising mechanism of action of novel antibody TB006 can be found on the TrueBinding website at www.truebinding.com.

In the Phase 1b/2 trial, administration of TB006 versus placebo reduced the Clinical Dementia Rating-Sum of Boxes (CDR-SB*) score, a patient and caregiver combined assessment, after just one month treatment. Through day 104, the data showed a treatment difference of 63 percent versus placebo, which represents a score change of -0.44 points (p=0.08); indicating a trend toward improvement in clinical function of patients in the analysis of the Intent-to-treat (ITT) population. Of note, at Day 36 TB006 versus placebo significantly improved not only Mini Mental State Examination (MMSE**) scores by 1.02 points (p=0.02), but also the percentage of responders (one or more points reduction of CDR-SB from the baseline, p=0.016). In addition, treatment with TB006 resulted in patient improvements across a range of disease severity, including within the difficult-to-treat moderate and severe patient population. In addition, TB006 significantly reduced Aβ 42 plasma levels and reduced amyloid plaques, further evidence of an impact on the underlying disease.

TB006 was safe and well tolerated through the observation period of 3.5 months. There were no treatment-related serious adverse events and no imaging-related abnormalities (ARIA). The most common adverse event (AE) was infusion reaction.

The trial was a seamless Phase 1b/2 double-blinded, placebo controlled, multicenter study conducted at 15 active sites in the U.S. to assess the safety and short-term efficacy of TB006 in 157 patients with mild to severe AD. Patients who met clinical diagnostic criteria for AD and had a screening MMSE <24 with no confounding neurologic or psychiatric disease were eligible. Amyloid positivity was not required for study participation. In the Phase 1b portion, three groups (140 mg, 420 mg, 1,000 mg) of eight patients received either weekly TB006 or placebo infusions in sequential ascending fashion for one month. In the Phase 2 portion, participants were randomized (1:1) to receive either TB006 (1,000 mg) or placebo weekly for one month. Other endpoints were the MMSE, neuropsychiatric inventory (NPI), CDR battery and plasma and imaging (MRI/PET) biomarkers. Cognition testing was performed at baseline and on days 15, 36, 64 and 104. Safety assessments were conducted at each visit.

An ongoing open-label extension study assessing monthly injections of TB006 at 4,000 mg in over 100 participants is generating long-term safety and efficacy data, with initial, interim data expected in the first quarter of 2023. A longer-term, 12-month, randomized, placebo-controlled Phase 2b trial is planned.

* CDR-SB is a numeric scale used to quantify the various severity of symptoms of dementia. Based on interviews of people living with AD and family/caregivers, qualified healthcare professionals assess cognitive and functional performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The total score of the six areas is the score of CDR-SB, and CDR-SB is also used as an appropriate item for evaluating the effectiveness of therapeutic drugs targeting the early stages of AD.

**The Mini Mental State Examination (MMSE) is a tool that can be used to systematically and thoroughly assess mental status. It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language.

About Alzheimer’s Disease
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative brain disorder. AD is the leading cause of dementia among older adults, affecting as many as 55 million patients worldwide¹ with an incidence expected to increase as the global population ages. AD is a type of dementia that begins with mild memory loss but eventually symptoms can become severe enough to affect other cognitive abilities that are required for daily living.

Major pathological hallmarks of AD include the formation of toxic oligomers in the brain involving the major proteins: amyloid beta (Aβ) peptides and phospho-tau, alpha synuclein, and ApoE4. Galectin-3 (Gal-3), an endogenous protein that is found at abnormally high levels in the brains of AD patients, has been shown to play a key role in AD pathology.² Gal-3 is involved in the sustained release of proinflammatory molecules, such as cytokines and chemokines which contribute to the toxic environment in the brain that drives the progression of AD². Gal-3 binds to Aβ peptides, p-Tau and other amyloid proteins, and acts as a glue, causing these proteins, which normally exist as monomers, to bind and form toxic oligomers. These oligomers cause plaque deposits in the brain, inflammation, and direct toxicity to intact neurons; thereby resulting in cognition defect symptoms in AD patients. While there is currently no known cure for AD, Gal-3 inhibition may provide a multi-pronged approach to the treatment of AD.

About TB006
TB006 is a humanized monoclonal antibody that, based on preclinical data and early clinical studies, has the potential to improve cognition and functioning of patients with Alzheimer’s disease (AD). In pre-clinical evaluations, Galectin-3 was shown to intrinsically promote the aggregation of Aβ and pTau proteins. In AD in vivo model studies, TB006 showed promising capabilities in significant reduction of the aggregation of Aβ/Tau proteins and neuroinflammation, and significant improvement of cognitive performance, which show potential therapeutic effect of TB006 in addressing underlying pathology and ameliorating the course of AD. Human safety of TB006 was established in a single, escalating dose safety and tolerability study, where doses of up to 5000 mg were safe and well tolerated. In a Phase 1b/2 proof-of-concept trial in mild to severe AD patients, TB006 demonstrated statistically significant improvements in cognition and functioning. TB006 is currently being evaluated in a Phase 2 open-label extension trial in patients with AD and in a Phase 2 trial in patients with acute ischemic stroke.

About TrueBinding, Inc.
TrueBinding Inc. is a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases, including Alzheimer’s disease (AD), as well as stroke, oncology and other serious diseases. The company is focused on rapidly advancing its lead drug candidate, TB006, a humanized monoclonal antibody targeting Galectin-3, that is being evaluated in a Phase 2 open-label extension trial in patients with AD and in a Phase 2 trial in patients with acute ischemic stroke. For more information, visit www.truebinding.com.

Contacts:

Dongxu Sun, PhD
Chief Executive Officer
dsun@truebinding.com
650.847.1117

References:

1. World Health Organization . Geneva, Switzerland: World Health Organization; 2021. Fact sheets of dementia [Internet] [cited 2022 Apr 13]. Available from: https:// www.who.int/news-room/fact-sheets/detail/dementia.
2. Boza-Serrano, A., Ruiz, R., Sanchez-Varo, R. et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019; 138:251–273. DOI:10.1007/s00401-019-02013-z https://pubmed.ncbi.nlm.nih.gov/31006066/

GlobeNewswire Distribution ID 8708878